Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

摘要: Four patients with refractory malignant B cell lymphomas were treated continuous intravenous (IV) infusions of murine monoclonal antibody (MoAb) 1F5 (anti-CD20) over five to ten days. Dose-dependent levels free serum detected in all patients. Two had circulating tumor cells and both cases 90% eliminated from the blood stream within four hours initiation serotherapy. Antigenic modulation did not occur, sustained reduction was observed throughout duration infusions. Serial bone marrow aspirations lymph node biopsies examined by immunoperoxidase immunofluorescence techniques ascertain MoAb penetration into extravascular sites. High doses (100 800 mg/m2/d high (13 190 micrograms/mL) required coat these compartments contrast low that adequate for depletion cells. Clinical response appeared correlate dose administered progressive disease (52 mg), stable (104 minor (1,032 partial (2,380 mg) consecutive The patient highest achieved a evaluable disease, but this remission brief (six weeks). This study demonstrates can be negligible toxicity infusion clinical responses obtained given greater than 1 g unmodified ten-day period.